Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 3–6 months
| Autor: | A. E. Karateev, E. Yu. Pogozheva, V. N. Amirjanova, E. S. Filatova, A. M. Lila, V. I. Mazurov, R. R. Samigullina, A. M. Dadalova, A. Yu. Dyo, D. S. Chakieva, A. A. Baranov, N. A. Lapkina, E. N. Koltsova, N. A. Kiryukhina, I. N. Shchendrigin, T. G. Rasevich, A. F. Davydova, I. V. Semizarova, I. A. Shafieva, I. B. Bashkova, D. A. Bobrikova, D. A. Murtazalieva, I. N. Kushnir, E. V. Kalinina, T. S. Salnikova, I. M. Marusenko, O. V. Semagina, I. B. Vinogradova, D. G. Krechikova, M. Yu. Semchenkova, E. L. Nasonov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Научно-практическая ревматология, Vol 59, Iss 4 (2021) |
| Druh dokumentu: | article |
| ISSN: | 1995-4484 1995-4492 |
| DOI: | 10.47360/1995-4484-2021-394-400 |
| Popis: | The JAK inhibitor tofacitinib (TOFA) blocks the intracellular signaling pathway that activates the synthesis of cytokines and mediators involved in the development of pain and central sensitization (CS), which determines the rapid analgesic effect. However, it is not clear how pain reduction is associated with achieving low activity in rheumatoid arthritis (RA).The aim of the study was to assess the relationship between the early clinical response to tofacitinib and a decrease in rheumatoid arthritis activity after 3 and 6 months.Material and methods. The study group consisted of 88 RA patients (age – 53±11.5 years; 79.3% of women) who received basic anti-inflammatory drugs (59.5% – methotrexate, 19.8% – leflunomide) and who were prescribed TOFA in a dose 10 mg/day. Seropositivity for rheumatoid factor was 89.8%; the value of the DAS28 index is 5.2±1.2. The severity of pain was assessed using the Brief Pain Inventory questionnaire, the neuropathic component of pain (NCP) – using the PainDETECT questionnaire, signs of CS – using the Central Sensitization Inventory (CSI) questionnaire in the early stages after the administration of TOFA, RA activity – using the DAS28-CRP index after 3 and 6 months.Results. The mean severity of pain at baseline was 5.3±2.0 on the visual analogue scale (VAS); 51.1% of patients had signs of CS (CSI>40), 15.9% had NCP (PainDETECT>18). 7 days after the start of therapy, there was a significant decrease in pain – to 4.1±1.8 according to VAS (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|